Jasper Therapeutics ( (JSPR) ) has provided an update.
On March 19, 2025, Jasper Therapeutics entered into a Sales Agreement with Jefferies LLC to potentially sell up to $100 million in common stock, providing flexibility in capital raising. The company also terminated its previous sales agreement with Cantor Fitzgerald & Co. on March 14, 2025, without incurring material penalties, having not sold any shares under that agreement.
More about Jasper Therapeutics
Jasper Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for hematologic diseases. The company primarily offers treatments that target the hematopoietic system, aiming to improve patient outcomes in conditions such as blood cancers and autoimmune diseases.
YTD Price Performance: -75.25%
Average Trading Volume: 567,625
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $78.42M
For a thorough assessment of JSPR stock, go to TipRanks’ Stock Analysis page.